Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Total Current Liabilities (2019 - 2025)

Historic Total Current Liabilities for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to $44.2 million.

  • Eton Pharmaceuticals' Total Current Liabilities rose 12389.28% to $44.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.2 million, marking a year-over-year increase of 12389.28%. This contributed to the annual value of $19.9 million for FY2024, which is 2281.88% up from last year.
  • Latest data reveals that Eton Pharmaceuticals reported Total Current Liabilities of $44.2 million as of Q3 2025, which was up 12389.28% from $38.6 million recorded in Q2 2025.
  • In the past 5 years, Eton Pharmaceuticals' Total Current Liabilities registered a high of $44.2 million during Q3 2025, and its lowest value of $3.1 million during Q2 2021.
  • In the last 5 years, Eton Pharmaceuticals' Total Current Liabilities had a median value of $9.6 million in 2023 and averaged $13.7 million.
  • Per our database at Business Quant, Eton Pharmaceuticals' Total Current Liabilities crashed by 1304.1% in 2022 and then soared by 15152.15% in 2023.
  • Eton Pharmaceuticals' Total Current Liabilities (Quarter) stood at $4.6 million in 2021, then skyrocketed by 41.75% to $6.5 million in 2022, then surged by 151.37% to $16.2 million in 2023, then increased by 22.82% to $19.9 million in 2024, then skyrocketed by 121.5% to $44.2 million in 2025.
  • Its last three reported values are $44.2 million in Q3 2025, $38.6 million for Q2 2025, and $25.3 million during Q1 2025.